MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC
Year: 2023
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: A.H. Nassar, E. Adib, D. Kaldas, J. Feng, T. AbuAli, J. Aredo, B. Fitzgerald, J. Bar, R. Thummalapalli, K. Parikh, R. Whitaker, L. Chen, J. Harris, A. Ayanambakkam, S. Farid, D. Owen, J. Sharp, A.I. Velazquez, M. Ragavan, A. D'aiello, H. Cheng, Z. Piotrowska, M. Wilgucki, J.E. Reuss, T. Patil, Y. Nie, J. Baena Espinar, H. Luders, C. Grohe, K. Sankar, M. Nagasaka, Y.P. Ashara, D.J. Kwiatkowski, R. Mak, A. Amini, A. Lobachov, J.J. Lin, T. Marron, H. Yu, J.W. Neal, H.A. Wakelee, F.A. Shepherd, T.J. Dilling, J.E. Gray, A.R. Naqash, S.B. Goldberg, S.Y. Kim
Institutions: Yale Cancer Center, Brigham and Women's Hospital, Moffitt Cancer Center, Princess Margaret Cancer Centre, City Of Hope National Medical Center, City of Hope, Icahn School of Medicine at Mount Sinai, Sheba Medical Center, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Vanderbilt-Ingram Cancer Center, Cedars-Sinai Medical Center, University of California, Irvine, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, The Ohio State University, University of California, San Francisco, Montefiore Health System, Massachusetts General Hospital, Georgetown University, MedStar Georgetown University Hospital, University of Colorado Anschutz, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Evangelische Lungenklinik Berlin
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4388046207